Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

January 4, 2019

Study Completion Date

January 11, 2019

Conditions
Alzheimer DiseaseAlzheimer Disease, Late Onset
Interventions
DEVICE

MemorEM 1000

The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.

Trial Locations (1)

33613

Byrd Alzheimer's Institute, University of South Florida, Tampa

Sponsors
All Listed Sponsors
collaborator

Byrd Alzheimer's Institute, University of South Florida

UNKNOWN

collaborator

University Diagnostic Institute, Tampa

UNKNOWN

collaborator

Invicro, Boston

UNKNOWN

collaborator

Left Coast Engineering, Escondido

UNKNOWN

lead

NeuroEM Therapeutics, Inc.

INDUSTRY

NCT02958930 - Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease | Biotech Hunter | Biotech Hunter